Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA warns Ranbaxy U.S. unit

This article was originally published in The Tan Sheet

Executive Summary

Ohm Labs' liquid manufacturing plant in Gloversville, N.Y., draws an FDA warning letter for good manufacturing practice deviations. The subsidiary of Indian pharma Ranbaxy acknowledged receiving the letter in a Dec. 24 release, adding the GMP violations were discovered during FDA inspections in July and August 2009. FDA found two other U.S. Ohm plants compliant during 2009 inspections, the North Brunswick, N.J., firm said. Ohm sells and distributes private-label and OTC products in the U.S

Related Content

Ohm Labs violations draw warning letter





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts